Black Hawk Acquisition Corporation shareholders approved the proposed business combination with Vesicor Therapeutics, Inc., along with proposals to domesticate the company as a Delaware corporation, adopt new organizational documents, elect five directors, and amend charter provisions. Approximately 77.3% of outstanding shares voted in favor, while holders of 2,089,162 ordinary shares redeemed their interests for an aggregate $25.15 million at approximately $12.04 per share. The company operates as a blank check company focused on effecting a merger with a private operating business.
